Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 6.5% in November

Cellectis S.A. (NASDAQ:CLLS) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 131,400 shares, a decline of 6.5% from the November 15th total of 140,500 shares. Based on an average daily volume of 56,100 shares, the short-interest ratio is presently 2.3 days.

Cellectis Trading Down 1.4 %

NASDAQ CLLS opened at $1.71 on Wednesday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 52 week low of $1.69 and a 52 week high of $3.77. The business has a 50 day moving average price of $1.91 and a 200-day moving average price of $2.08. The company has a market cap of $94.77 million, a price-to-earnings ratio of -1.31 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the previous year, the business posted ($0.31) EPS. As a group, equities analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on CLLS shares. StockNews.com began coverage on Cellectis in a report on Sunday. They set a “sell” rating on the stock. Barclays cut their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Institutional Trading of Cellectis

Several institutional investors have recently made changes to their positions in CLLS. XTX Topco Ltd purchased a new position in shares of Cellectis in the 2nd quarter worth approximately $29,000. First Affirmative Financial Network purchased a new position in shares of Cellectis during the 3rd quarter valued at $45,000. Principal Financial Group Inc. boosted its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC boosted its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the period. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.